KOLs Suggest Catalyst Pharmaceutical's (CPRX) Firdapse Not Hurt by Jacobus - Piper Jaffray
Tweet Send to a Friend
Piper Jaffray analyst Joseph Catanzaro reiterated an Overweight rating and $8.00 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX), saying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
